Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients

Cardiology

Volumn 114, Issue 3, 2009, Pages 192-198

  Kush, Debra ^a   Hu, Da Yi ^b   Ye, Ping ^c   Kim, Hyo Soo ^d   Chen, Erluo ^a   Sirah, Waheeda ^a   McCrary Sisk, Christine ^a   Paolini, John F ^a   MacCubbin, Darbie ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d Seoul National University Hospital   (South Korea)

Author keywords

Extended release niacin; Flushing; Laropiprant

Indexed keywords

LAROPIPRANT; NICOTINIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FLUSHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADULT; AGED; ANTILIPEMIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; FLUSHING; HUMANS; INDOLES; MALE; MIDDLE AGED; NIACIN;

EID: 67650132974     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228585     Document Type: Article

References (21)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
2. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592. (Pubitemid 33126837)
3. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ: Types of change in coronary stenosis severity and their relative importance in overall progression and regression in coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment Study. Ann NY Acad Sci 1995;748:407-417.
4. Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, Zhao XQ, Albers JJ, Knopp RH: Moderate dose, 3-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997;80:111-115. (Pubitemid 27329205)
5. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
6. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
7. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, Burrows E, Retzlaff B, Poole M: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-650.
8. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004;62:229-234. (Pubitemid 39193956)
9. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J: Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74U-81U.
10. Morgan JM, Capuzzi DM, Guyton JR: A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998;82:29U-34U.
11. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA: Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994;154:1586-1595. (Pubitemid 24242345)
12. Mills E, Prousky J, Raskin G, Gagnier J, Rachlis B, Montori VM, Juurlink D: The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol 2003;3:4-11.
13. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C: Discontinuation of lipid modifying drugs among commercially insured U.S. patients in recent clinical practice. Am J Cardiol 2007;99:530-534. (Pubitemid 46215558)
14. Abbott Laboratories: Niaspan® (niacin extended-release tablets US prescribing information). Available at: http://www.rxabbott. com/pdf.niaspan. Accessed June 22, 2009.
15. Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, Waters MG: Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006;103:6682-6687.
16. Kaijser L, Eklund B, Olsson AG, Carlson LA: Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979;57:114-117. (Pubitemid 9187410)
17. Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Levesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM: Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-f luoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclope nta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007;50:794-806.
18. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM: Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-630.
19. Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, McCrary Sisk C, Pasternak RC, Paolini JF: Lipid-modifying efficacy and tolerability of extended release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-1970.
20. Norquist JM, Watson DJ, Yu Q, Paolini JF, McQuarrie K, Santanello NC: Development and validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 2007;23:1549-1560. (Pubitemid 47122163)
21. Kamal-Bahl S, Burke TA, Watson DJ, Wentworth CE: Dosage, titration and gaps in treatment with extended-release niacin in clinical practice. Curr Med Res Opin 2008;24:1817-1821. (Pubitemid 351929079)